Ponatinib and blinatumomab for patients with Philadelphia chromosome-positive ALL

Описание к видео Ponatinib and blinatumomab for patients with Philadelphia chromosome-positive ALL

Dr Nicholas Short speaks to ecancer at the EHA 2022 congress about a study looking at ponatinib and blinatumomab for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL).

He explains that 55 patients were treated with the patients seeing high rates of complete molecular response and durability.

Prof Short believes that if the data can be confirmed with longer follow up then this could be a potential paradigm shift for the treatment of Philadelphia chromosome-positive ALL.

Комментарии

Информация по комментариям в разработке

Похожие видео